INN Working Document 16.394
08/07/2016

Addendum[1] to
"The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances" WHO/EMP/RHT/TSN/2013.1

Programme on International Nonproprietary Names (INN)

Technologies Standards and Norms (TSN)
Regulation of Medicines and other health technologies (RHT)

World Health Organization, Geneva

Addendum[1] to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2013.1

[1] This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of *"The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances"* 2013.

-apt- **aptamers, classical and mirror ones**

(a) avacincaptad pegol (113), egaptivon pegol (111), emapticap pegol (108), lexaptepid pegol (108), olaptesed pegol (109), pegaptanib (88)

(b) *-vaptan* stem: conivaptan (82), lixivaptan (83), mozavaptan (87), nelivaptan (98), relcovaptan (82), ribuvaptan (110), satavaptan (93), tolvaptan (83). aptazapine(50), aptiganel (72), aptocaine (21), captamine (18), captodiame (06), captopril (39), danegaptide (101), daptomycin (58), icrocaptide (89), mercaptamine (01), mercaptomerin (01), mercaptopurine (06), naptumomab estafenatox (96), rotigaptide (94), sodium borocaptate (^{10}B) (62), sodium stibocaptate (17), taplitumomab paptox (84)

(c) pegnivacogin (106)

-cel **cell therapy products**

Please refer to the Annex "General policies for cell therapy products**".**

audencel (115), cenplacel (115), eltrapuldencel (115), palucorcel (115), spanlecortemlocel (113 amendment in 115), tonogenconcel (115), vandefitemcel (115)

-degib **SMO receptor antagonists**

glasdegib (111), patidegib (111), sonidegib (107), taladegib (110), vismodegib (103)

-dotin **synthetic derivatives of dolastatin series**

aprutumab ixadotin (115), brentuximab vedotin (103), cemadotin (75), denintuzumab mafodotin (111), depatuxizumab mafodotin (115), enfortumab

vedotin (109), glembatumumab vedotin (113), indusatumab vedotin (112), lifastuzumab vedotin (110), lupartumab amadotin (115), pinatuzumab vedotin (108), polatuzumab vedotin (108), soblidotin (84), sofituzumab vedotin (110), tisotumab vedotin (113), tasidotin (93), telisotuzumab vedotin (115), vandortuzumab vedotin (113), vorsetuzumab mafodotin (107)

-fenacin **muscarinic receptor antagonists**

afacifenacin (101), darifenacin (70), imidafenacin (90), revefenacin (114), solifenacin (85), tarafenacin (100), tofenacin (15), zamifenacin (68)

-fensine **norepinephrine, serotonin, dopamine reuptake inhibitors**

brasofensine (76), diclofensine (44), liafensine (109), nomifensine (24), perafensine (44), tesofensine (89)

-imod immunomodulators, both stimulant/suppressive and stimulant

-tolimod **toll-like receptors (TLR) agonists**

agatolimod (98), cobitolimod (113), lefitolimod (113), entolimod (108), motolimod (112), rintatolimod (102), vesatolimod (113)

-isant **histamine H_3 receptor antagonists**

bavisant (103), cipralisant (85), enerisant (113), irdabisant (105), pitolisant (100)

-glurant **metabotropic glutamate receptor antagonists / negative allosteric modulators**

basimglurant (109), decoglurant (109), dipraglurant (102), mavoglurant (104), raseglurant (102), remeglurant (109)

-nepag **prostaglandins receptors agonists, non-prostanoids**

(a) aganepag (104), evatanepag (101), omidenepag (114), ralinepag (112), simenepag (103), taprenepag (103)

(c) selexipag (102)

-prazan **proton pump inhibitors, not dependent on acid activation**

linaprazan (92), revaprazan (91), soraprazan (88), tegoprazan (113), vonoprazan (106)

-rafenib **Raf (rapidely accelerated fibrosarcoma) kinase inhibitors**

agerafenib (115), dabrafenib (105), encorafenib (109), sorafenib (88), regorafenib (100), vemurafenib (103)

-siran **small interfering RNA**

asvasiran (111), bamosiran (106), bevasiranib (108), cemdisiran (115), fitusiran (113), givosiran (115), inclisiran (115), patisiran (109), revusiran (111)

-tansine **maytansinoid derivatives, antineoplastics**

emtansine (such as laprituximab emtansine (114), naratuximab emtansine (114) , trastuzumab emtansine (103))
maitansine (40)
mertansine (such as cantuzumab mertansine (105), lorvotuzumab mertansine (103))
ravtansine (such as anetumab ravtansine (109), cantuzumab ravtansine (105), coltuximab ravtansine (109), indatuximab ravtansine (105))
soravtansine (such as mirvetuximab soravtansine (113))

-tide peptides and glycopeptides (for special groups of peptides see –actide, -pressin, relin, -tocin)

-ritide **natriuretic peptides**

anaritide (57), carperitide (65), cenderitide (105), nesiritide (80), ularitide (69) vosoritide (112)

-tinib tyrosine kinase inhibitors

-citinib **Janus kinase inhibitors, antineoplastics**

baricitinib (107), itacitinib (115), oclacitinib (105), peficitinib (111), solcitinib (112), tofacitinib (105), upadacitinib (115)

-metinib **MEK (MAPK[#] kinase) tyrosine kinase inhibitors**

binimetinib (109), cobimetinib (107), pexmetinib (110), ralimetinib (109), refametinib (106), selumetinib (100), trametinib (105)

[#] MAPK: mitogen activated protein kinase

-traline **serotonin reuptake inhibitors**

dasotraline (110), indatraline(54), lometraline (28), sertraline (48), tametraline (46)

-vir antivirals

-asvir **antivirals, hepatitis C Virus (HCV) NS5A inhibitors**

daclatasvir (107), elbasvir (111), ledipasvir (109), odalasvir (111), ombitasvir